Abstract Library

#4650 Whole exome sequencing in pulmonary neuroendocrine neoplasms: Findings from a pilot investigation

Introduction: The molecular landscape of lung neuroendocrine tumours (NETs) is still poorly characterised. Lung NETs main prognostic factors currently include stage, histotype, grade, location, and demographic parameters, but molecular biomarkers are still not available, limiting the possibility for personalised therapeutic strategies.

Conference:

Presenting Author:

Authors: Martiradonna M, Pecora G, Mancini C, de Vitis C, Telese S,

Keywords: carcinoid, PBMC, NGS, Whole exome sequencing, WES, FFPE, Lung NET, molecular landscape,

#4604 Germline predisposition to neuroendocrine tumours of the pancreas (pNEN) based on mutations in DNA repair genes – BRCA1, BRCA2, PALB2, CHEK2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MUTYH, STK11

Introduction: Neuroendocrine tumours of the pancreas (pNEN) rank as the second most common epithelial neoplasms after pancreatic adenocarcinoma, with increasing prevalence and a mortality rate of 60%. Identifying germline mutations in DNA repair genes such as CHEK2, BRCA1/2, and MUTYH within pNEN cases may pave the way for personalised diagnostics and therapies.

Conference:

Presenting Author:

Authors: Jurecka Lubieniecka B, Ros-Mazurczyuk M, Oczko-Wojciechowska M, Cortez A, Handkiewicz-Junak D,

Keywords: pNEN, DNA repair genes,

#4602 The role of microbiome diversity in neuroendocrine tumour (NET) development and progression: Insights from a cohort study

Introduction: The gut microbiome may influence neuroendocrine tumour (NET) development, particularly gastrointestinal NETs, yet data on this connection within Pakistan are limited. This study explores microbiome diversity’s role in NET progression.

Conference:

Presenting Author: Fatima A

Authors: Fatima A,

Keywords: Bacterial imbalance, Prognostic biomarker,

#4592 Uncovering cell-state heterogeneity in large-cell panNEC indicates potentially targetable aberrant brain type neuronal de-differentiation

Introduction: Classification and treatment of high-grade pancreatic neuroendocrine carcinoma (panNEC), particularly those with large-cell morphology, present significant clinical challenges due to considerable inter- and intra-patient tumour heterogeneity.

Conference:

Presenting Author: Debnath O

Authors: Debnath O, Berger H, Detjen K, Kirchner P, Marinoni I,

Keywords: pancreatic neuroendocrine carcinoma, single cell, personalised medicine,

#4591 Efficacy of Trabectedin and Olaparib in homologous repair deficient neuroendocrine neoplasms – A subgroup analysis of the TOP-ART / PMO-1603 trial

Introduction: Genomic alterations resulting in homologous recombination deficiency (HRD) occur in a variety of cancers including neuroendocrine neoplasms (NEN). HRD-positive tumours are sensitive to PARP inhibitors such as olaparib. The DNA minor groove binder trabectedin leads to DNA double strand breaks and PARP activation. The combination of Trabectedin + Olaparib (TrO) may therefore have synergistic effects in HRD-positive tumours.

Conference:

Presenting Author: Apostolidis L

Authors: Apostolidis L, Ruebsam M, Teleanu M, Wagner S, Dorman K,

Keywords: Neuroendocrine Tumour, Neuroendocrine Carcinoma, targeted therapy, chemotherapy, HRD, olaparib, trabectedin, net, nec,